Monica Heger tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb.
PacBio is looking to increase the yield and reduce the cost of the protocol, which enables long reads and accurate sequencing.
Despite initial promise, NGS-based MRD detection has not been broadly adopted, but improvements in technology and more clinical utility data may change that.
Meridian CEO Jack Kenny said the firm needs to develop a new MDx platform, while Genapsys resurfaced with an update on its portable sequencing platform.
CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.
Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
The company plans to focus on increasing its NIPT reimbursement as well as on pharmaceutical deals for its oncology test and launching a kidney transplantation test.
The company is also looking to expand the use of its FDA-approved ClonoSeq assay, which has US FDA approval for MRD detection in acute lymphocytic leukemia and multiple myeloma.
A busy second day of the JP Morgan conference saw Thermo Fisher's Marc Casper discuss the firm's R&D focus and Exact Sciences' Kevin Conroy discuss plans for Cologuard sales growth.
The firm's fourth quarter preliminary revenues increased by 11 percent to $865 million year over year, while full-year revenues jumped by 21 percent to $3.3 billion.
The researchers plan to commercialize the method, which they said will help characterize how microbes respond to different environmental conditions.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.